Published in Nat Biotechnol on February 20, 2005
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity (2009) 3.21
Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol (2009) 3.06
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 2.69
PD-1 signaling in primary T cells. Immunol Rev (2009) 2.66
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med (2008) 2.64
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol (2008) 2.54
Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood (2006) 2.11
Display technologies: application for the discovery of drug and gene delivery agents. Adv Drug Deliv Rev (2006) 1.92
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med (2015) 1.92
Why must T cells be cross-reactive? Nat Rev Immunol (2012) 1.88
T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology (2009) 1.85
High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol (2007) 1.85
Treating cancer with genetically engineered T cells. Trends Biotechnol (2011) 1.83
TCR affinity and specificity requirements for human regulatory T-cell function. Blood (2012) 1.69
Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood (2013) 1.63
Monoclonal TCR-redirected tumor cell killing. Nat Med (2012) 1.57
Immunotherapeutic approaches for glioma. Crit Rev Immunol (2009) 1.55
TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms. J Immunol (2011) 1.46
Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol (2006) 1.44
Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol (2012) 1.41
In Silico Generation of Peptides by Replica Exchange Monte Carlo: Docking-Based Optimization of Maltose-Binding-Protein Ligands. PLoS One (2015) 1.40
Clonotypically similar hybrid αβ T cell receptors can exhibit markedly different surface expression, antigen specificity and cross-reactivity. Clin Exp Immunol (2015) 1.40
High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med (2013) 1.40
Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity. Protein Sci (2006) 1.31
Structural and biophysical determinants of αβ T-cell antigen recognition. Immunology (2012) 1.30
A new generation of protein display scaffolds for molecular recognition. Protein Sci (2006) 1.29
T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother (2008) 1.24
Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci U S A (2009) 1.23
Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J Exp Med (2009) 1.21
Soluble plasma HLA peptidome as a potential source for cancer biomarkers. Proc Natl Acad Sci U S A (2010) 1.18
T cell receptor gene therapy for cancer. Hum Gene Ther (2009) 1.17
Structure-based design of a T-cell receptor leads to nearly 100-fold improvement in binding affinity for pepMHC. Proteins (2009) 1.16
Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol (2007) 1.06
Genetic engineering of T cells for adoptive immunotherapy. Immunol Res (2008) 1.05
Antigen potency and maximal efficacy reveal a mechanism of efficient T cell activation. Sci Signal (2011) 1.04
Engineering higher affinity T cell receptors using a T cell display system. J Immunol Methods (2008) 1.00
Fluorine substitutions in an antigenic peptide selectively modulate T-cell receptor binding in a minimally perturbing manner. Biochem J (2009) 1.00
Enhanced T-cell signaling in cells bearing linker for activation of T-cell (LAT) molecules resistant to ubiquitylation. Proc Natl Acad Sci U S A (2011) 0.99
Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity. Mol Ther (2012) 0.99
Diversity-oriented approaches for interrogating T-cell receptor repertoire, ligand recognition, and function. Immunol Rev (2012) 0.98
Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors. Protein Eng Des Sel (2010) 0.98
Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther (2015) 0.97
Computational design of the affinity and specificity of a therapeutic T cell receptor. PLoS Comput Biol (2014) 0.96
Improving the safety of cell therapy with the TK-suicide gene. Front Pharmacol (2015) 0.96
Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining. J Immunol (2011) 0.94
Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev (2014) 0.94
T-cell receptor specificity maintained by altered thermodynamics. J Biol Chem (2013) 0.94
Primer sets for cloning the human repertoire of T cell Receptor Variable regions. BMC Immunol (2008) 0.93
T-cell receptor (TCR)-peptide specificity overrides affinity-enhancing TCR-major histocompatibility complex interactions. J Biol Chem (2013) 0.93
New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell (2015) 0.93
Molecular architecture of the αβ T cell receptor-CD3 complex. Proc Natl Acad Sci U S A (2014) 0.93
Survivin-specific T cell receptor targets tumor but not T cells. J Clin Invest (2014) 0.91
Molecular immunology lessons from therapeutic T-cell receptor gene transfer. Immunology (2010) 0.91
Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes. AIDS (2010) 0.91
Subtle affinity-enhancing mutations in a myelin oligodendrocyte glycoprotein-specific TCR alter specificity and generate new self-reactivity. J Immunol (2009) 0.91
Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain ValphaVbeta fragments. Mol Immunol (2008) 0.90
Ca2+ release from the endoplasmic reticulum of NY-ESO-1-specific T cells is modulated by the affinity of TCR and by the use of the CD8 coreceptor. J Immunol (2010) 0.90
Can oligomeric T-cell receptor be used as a tool to detect viral peptide epitopes on infected cells? Clin Immunol (2008) 0.89
Driving gene-engineered T cell immunotherapy of cancer. Cell Res (2016) 0.89
The structure of superantigen complexed with TCR and MHC reveals novel insights into superantigenic T cell activation. Nat Commun (2010) 0.89
MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. Cancer Immunol Immunother (2012) 0.88
Human MHC Class I-restricted high avidity CD4(+) T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. Oncoimmunology (2013) 0.88
Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens. Clin Exp Immunol (2005) 0.88
Adoptive T-cell therapy for B-cell malignancies. Expert Rev Hematol (2009) 0.88
Engineering T cells for cancer: our synthetic future. Immunol Rev (2014) 0.88
Increased Peptide Contacts Govern High Affinity Binding of a Modified TCR Whilst Maintaining a Native pMHC Docking Mode. Front Immunol (2013) 0.88
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother (2012) 0.88
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Front Immunol (2013) 0.87
Improving TCR Gene Therapy for Treatment of Haematological Malignancies. Adv Hematol (2012) 0.87
Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses. Gene Ther (2012) 0.86
The Goldilocks model for TCR-too much attraction might not be best for vaccine design. PLoS Biol (2010) 0.86
ImmTACs: Novel bi-specific agents for targeted cancer therapy. Oncoimmunology (2013) 0.86
Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells. Oncoimmunology (2013) 0.86
Engineering improved T cell receptors using an alanine-scan guided T cell display selection system. J Immunol Methods (2013) 0.85
The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors. Chin J Cancer (2014) 0.85
Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. Front Immunol (2013) 0.84
Combinations of affinity-enhancing mutations in a T cell receptor reveal highly nonadditive effects within and between complementarity determining regions and chains. Biochemistry (2010) 0.84
HIV-1 functional cure: will the dream come true? BMC Med (2015) 0.84
Specific roles of each TCR hemichain in generating functional chain-centric TCR. J Immunol (2015) 0.84
Methods for quantifying T cell receptor binding affinities and thermodynamics. Methods Enzymol (2009) 0.84
Structure-Based, Rational Design of T Cell Receptors. Front Immunol (2013) 0.84
Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. Pharmaceuticals (Basel) (2014) 0.84
Rational design of T cell receptors with enhanced sensitivity for antigen. PLoS One (2011) 0.83
Genetically engineered T cells for the treatment of cancer. J Intern Med (2013) 0.83
Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes. J Mol Biol (2013) 0.83
Specific increase in potency via structure-based design of a TCR. J Immunol (2014) 0.82
The T cell antigen receptor: the Swiss army knife of the immune system. Clin Exp Immunol (2015) 0.82
Structure of Staphylococcal Enterotoxin E in Complex with TCR Defines the Role of TCR Loop Positioning in Superantigen Recognition. PLoS One (2015) 0.82
Chaperone-assisted thermostability engineering of a soluble T cell receptor using phage display. Sci Rep (2013) 0.81
Engineering T Cells to Functionally Cure HIV-1 Infection. Mol Ther (2015) 0.81
T cell engineering as therapy for cancer and HIV: our synthetic future. Philos Trans R Soc Lond B Biol Sci (2015) 0.80
Changing the peptide specificity of a human T-cell receptor by directed evolution. Nat Commun (2014) 0.80
Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. Front Immunol (2015) 0.80
Architecture of a minimal signaling pathway explains the T-cell response to a 1 million-fold variation in antigen affinity and dose. Proc Natl Acad Sci U S A (2016) 0.80
How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer. Front Immunol (2012) 0.79
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors. Trends Pharmacol Sci (2015) 0.79
Adoptive immunotherapy of cancer: Gene transfer of T cell specificity. Self Nonself (2011) 0.78
Genomewide association study of leprosy. N Engl J Med (2009) 8.17
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol (2003) 6.82
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet (2009) 6.42
Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ Res (2003) 4.29
US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis (2015) 3.94
AAV vector integration sites in mouse hepatocellular carcinoma. Science (2007) 3.73
Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol (2003) 3.54
Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell (2002) 3.50
Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell (2003) 3.42
Uniqueness theorems in bioluminescence tomography. Med Phys (2004) 3.32
The genetic map of Artemisia annua L. identifies loci affecting yield of the antimalarial drug artemisinin. Science (2010) 2.92
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91
Treatment of neural injury with marrow stromal cells. Lancet Neurol (2002) 2.89
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2005) 2.83
Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng (2003) 2.75
Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab (2005) 2.65
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med (2008) 2.64
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet (2010) 2.62
Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. J Neurosci Res (2003) 2.61
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol (2008) 2.54
CD4-CD8 lineage commitment is regulated by a silencer element at the ThPOK transcription-factor locus. Immunity (2008) 2.49
A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease. PLoS Genet (2009) 2.45
Ischemic rat brain extracts induce human marrow stromal cell growth factor production. Neuropathology (2002) 2.38
Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A (2010) 2.32
Arabidopsis ABA INSENSITIVE4 regulates lipid mobilization in the embryo and reveals repression of seed germination by the endosperm. Plant Cell (2006) 2.27
Principled sure independence screening for Cox models with ultra-high-dimensional covariates. J Multivar Anal (2012) 2.23
Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med (2005) 2.22
Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med (2006) 2.17
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 2.15
Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells (2012) 2.14
Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol (2005) 2.11
Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke. J Cereb Blood Flow Metab (2006) 2.10
Spatial cluster detection for censored outcome data. Biometrics (2007) 2.07
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med (2013) 2.07
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell (2012) 2.04
mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia (2005) 2.04
A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci U S A (2006) 2.03
The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. EuroIntervention (2013) 2.02
Human TCR-binding affinity is governed by MHC class restriction. J Immunol (2007) 2.02
Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjögren's syndrome: findings in humans and mice. Arthritis Rheum (2008) 2.01
Genetic bio-ancestry and social construction of racial classification in social surveys in the contemporary United States. Demography (2014) 2.00
A Papaver somniferum 10-gene cluster for synthesis of the anticancer alkaloid noscapine. Science (2012) 2.00
TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J Exp Med (2008) 1.99
Engineering of human pluripotent stem cells by AAV-mediated gene targeting. Mol Ther (2010) 1.99
Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells--implications for pregnancy-induced protection against breast cancer. Stem Cells (2008) 1.96
Identification of two new loci at IL23R and RAB32 that influence susceptibility to leprosy. Nat Genet (2011) 1.95
Parental decision making about the HPV vaccine. Cancer Epidemiol Biomarkers Prev (2010) 1.94
TCR affinity and negative regulation limit autoimmunity. Nat Med (2004) 1.94
Transcriptome analysis of root transporters reveals participation of multiple gene families in the response to cation stress. Plant J (2003) 1.93
The CD8 T cell coreceptor exhibits disproportionate biological activity at extremely low binding affinities. J Biol Chem (2003) 1.92
NF-kappa B-inducing kinase establishes self-tolerance in a thymic stroma-dependent manner. J Immunol (2004) 1.92
Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging (2007) 1.90
Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke. J Cereb Blood Flow Metab (2007) 1.89
A simple, rapid, high-fidelity and cost-effective PCR-based two-step DNA synthesis method for long gene sequences. Nucleic Acids Res (2004) 1.86
Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats. J Cereb Blood Flow Metab (2013) 1.85
Human bone marrow stromal cell cultures conditioned by traumatic brain tissue extracts: growth factor production. J Neurosci Res (2002) 1.85
High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol (2007) 1.85
Residential exposure to petrochemicals and the risk of leukemia: using geographic information system tools to estimate individual-level residential exposure. Am J Epidemiol (2006) 1.84
The Wnt signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1-induced tumorigenesis. J Biol Chem (2006) 1.80
Genome-wide ORFeome cloning and analysis of Arabidopsis transcription factor genes. Plant Physiol (2004) 1.79
Measuring sleep: accuracy, sensitivity, and specificity of wrist actigraphy compared to polysomnography. Sleep (2013) 1.78
A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet (2011) 1.77
Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J Neurotrauma (2007) 1.76
Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol (2012) 1.76
PCR-based accurate synthesis of long DNA sequences. Nat Protoc (2006) 1.75
Chirality transfer from guest chiral metal complexes to inorganic framework: the role of hydrogen bonding. Chemistry (2003) 1.73
Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.70
TCR affinity and specificity requirements for human regulatory T-cell function. Blood (2012) 1.69
Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res (2005) 1.69
Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med (2013) 1.68
Surgery and brain atrophy in cognitively normal elderly subjects and subjects diagnosed with mild cognitive impairment. Anesthesiology (2012) 1.67
EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. Mol Cell (2012) 1.65
Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res (2004) 1.64
Molecular genetic evidence for the role of SGT1 in the intramolecular complementation of Bs2 protein activity in Nicotiana benthamiana. Plant Cell (2005) 1.63
Folding of Toll-like receptors by the HSP90 paralogue gp96 requires a substrate-specific cochaperone. Nat Commun (2010) 1.62
Who's in favor of translational cell therapy for stroke: STEPS forward please? Cell Transplant (2009) 1.60
Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models. Proc Natl Acad Sci U S A (2006) 1.60
MCP-1, MIP-1, IL-8 and ischemic cerebral tissue enhance human bone marrow stromal cell migration in interface culture. Hematology (2002) 1.59
Bone marrow-derived mesenchymal stromal cells accelerate wound healing in the rat. Wound Repair Regen (2006) 1.58
Monoclonal TCR-redirected tumor cell killing. Nat Med (2012) 1.57
Intravenous administration of human umbilical cord blood reduces neurological deficit in the rat after traumatic brain injury. Cell Transplant (2002) 1.57
One-year follow-up after bone marrow stromal cell treatment in middle-aged female rats with stroke. Stroke (2007) 1.57
Innate-like control of human iNKT cell autoreactivity via the hypervariable CDR3beta loop. PLoS Biol (2010) 1.56
Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. JACC Cardiovasc Interv (2009) 1.56
Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo. J Nucl Med (2004) 1.56
Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck. Head Neck (2004) 1.55
Endothelial nitric oxide synthase regulates brain-derived neurotrophic factor expression and neurogenesis after stroke in mice. J Neurosci (2005) 1.54